Published in BMJ on July 28, 2009
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women. Am J Epidemiol (2013) 1.56
Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev (2013) 1.53
Characteristics and screening history of women diagnosed with cervical cancer aged 20-29 years. Br J Cancer (2013) 1.33
Predictors of low cervical cancer screening among immigrant women in Ontario, Canada. BMC Womens Health (2011) 1.25
Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. Br J Cancer (2012) 1.07
Breast cancer screening: are we seeing the benefit? BMC Med (2012) 1.02
Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol (2013) 1.02
Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health (2012) 1.02
Cervical carcinoma rates among young females in the United States. Obstet Gynecol (2012) 1.00
Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med (2014) 1.00
Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer (2010) 1.00
Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer (2014) 1.00
Increasing rates of cervical cancer in young women in England: an analysis of national data 1982-2006. Br J Cancer (2011) 1.00
Association between human papillomavirus vaccine status and other cervical cancer risk factors. Vaccine (2014) 0.99
Evaluating cytology for the detection of invasive cervical cancer. Cytopathology (2015) 0.98
Cervical cancer prevention program in Jakarta, Indonesia: See and Treat model in developing country. J Gynecol Oncol (2012) 0.95
Factors associated with participation in cancer prevention and control studies among rural Appalachian women. Fam Community Health (2011) 0.95
The road ahead for cervical cancer prevention and control. Curr Oncol (2014) 0.94
The association of type and number of chronic diseases with breast, cervical, and colorectal cancer screening. J Am Board Fam Med (2014) 0.93
Determinants of acceptance of cervical cancer screening in Dar es Salaam, Tanzania. BMC Public Health (2012) 0.91
Measuring the nature and duration of symptoms of cervical cancer in young women: developing an interview-based approach. BMC Womens Health (2013) 0.90
Patterns and determinants of breast and cervical cancer non-screening among Appalachian women. Women Health (2013) 0.88
Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme. PLoS One (2016) 0.86
Cytological pattern of cervical Papanicolaou smear in eastern region of Saudi Arabia. J Cytol (2011) 0.86
Expenditure and resource utilisation for cervical screening in Australia. BMC Health Serv Res (2012) 0.86
Performance of papanicolaou testing and detection of cervical carcinoma in situ in participants of organized cervical cancer screening in South Korea. PLoS One (2012) 0.84
Access to cancer screening in people with learning disabilities in the UK: cohort study in the health improvement network, a primary care research database. PLoS One (2012) 0.83
Cervical screening and cervical cancer death among older women: a population-based, case-control study. Am J Epidemiol (2014) 0.81
Cervical cancer screening service utilisation in UK. Sci Rep (2013) 0.81
Cervical excisional treatment of young women: a population-based study. Gynecol Oncol (2014) 0.80
Human papillomavirus disease and vaccines in adolescents. Adolesc Med State Art Rev (2010) 0.80
Cervical cancer screening in older women: new evidence and knowledge gaps. PLoS Med (2014) 0.80
Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.79
Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer (2016) 0.79
HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer (2012) 0.79
Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral. PLoS One (2014) 0.78
Cervical Cancer Screening: Defining the Need for Research. Geburtshilfe Frauenheilkd (2013) 0.78
Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. BMC Cancer (2012) 0.77
Do invitations for cervical screening provide sufficient information to enable informed choice? A cross-sectional study of invitations for publicly funded cervical screening. J R Soc Med (2016) 0.77
Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer (2016) 0.77
An ongoing case-control study to evaluate the NHS breast screening programme. BMC Cancer (2013) 0.76
Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000-2011. PLoS One (2016) 0.75
Cervical cytology and the diagnosis of cervical cancer in older women. J Med Screen (2015) 0.75
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. BMC Public Health (2017) 0.75
Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention. BMJ Open (2016) 0.75
An ongoing case-control study to evaluate the NHS Bowel Cancer Screening Programme. BMC Cancer (2014) 0.75
Cervical intraepithelial lesions in females attending Women's Health Clinics in Alexandria, Egypt. Cytojournal (2015) 0.75
Evaluation of the Cobas 4800 HPV Test for Detecting High-Risk Human Papilloma-Virus in Cervical Cytology Specimens. Pathogens (2012) 0.75
Factors Affecting Gynecologic and Sexual Assessment in Older Women: A Lesson for Primary Care Providers. Healthcare (Basel) (2015) 0.75
Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a population-based cohort study. Can J Kidney Health Dis (2016) 0.75
Changing pattern of epithelial cell abnormalities using revised Bethesda system. Iran J Basic Med Sci (2014) 0.75
Does CIN2 Have the Same Aggressive Potential As CIN3? A Secondary Analysis of High-Grade Cytology Recurrence in Women Treated with Cold-Coagulation Cervical Treatment. Geburtshilfe Frauenheilkd (2017) 0.75
Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. Br J Gen Pract (2016) 0.75
HPV-DNA testing for patients with ASC-US helps identify the women who have a high risk for precancerous cervical lesions. J Med Life (2014) 0.75
Screening adolescents and young women. Obstet Gynecol Clin North Am (2013) 0.75
Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014. J Gynecol Oncol (2017) 0.75
[Screening for cervical and breast cancer]. Pathologe (2016) 0.75
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet (2006) 5.65
American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin (2002) 5.56
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Evaluation of screening for cervical cancer in Sweden: trends in incidence and mortality 1958-1980. Int J Epidemiol (1985) 2.64
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev (2005) 2.03
Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer (1999) 1.56
Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol (2007) 1.40
Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Health Care (2008) 1.25
Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer (2004) 1.20
Cervical screening in 20-24-year olds. J Med Screen (2006) 1.06
Cervical cancer in women aged less than 25: East Kent experience. J Obstet Gynaecol (2007) 1.06
A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. Cancer Causes Control (2008) 1.05
Cervical screening in young women aged 20-24 years. J Fam Plann Reprod Health Care (2008) 1.04
Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. Eur J Cancer (2007) 0.97
Screening for squamous cervical cancer--the duration of low risk following negative results in cervical cytology test: introduction. IARC Working Group on Cervical Cancer Screening. IARC Sci Publ (1986) 0.97
Cervical screening in under 25s: a high-risk young population. Eur J Obstet Gynecol Reprod Biol (2007) 0.95
The cytological screening turned out effective also for adenocarcinoma: a population-based case-control study in Trento, Italy. Eur J Cancer Prev (2007) 0.91
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet (2003) 6.15
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol (2010) 2.63
Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol (2006) 2.59
Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. Gastroenterology (2004) 2.55
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol (2012) 2.38
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst (2008) 2.36
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol (2013) 2.28
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol (2011) 2.26
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine (2006) 2.25
Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2008) 2.24
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev (2008) 2.20
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol (2005) 2.12
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol (2009) 1.96
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol (2004) 1.95
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res (2006) 1.80
A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer (2005) 1.70
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol (2011) 1.66
How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer (2009) 1.65
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res (2010) 1.64
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat (2006) 1.61
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila) (2012) 1.59
Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol (2012) 1.57
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst (2013) 1.51
A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer (2012) 1.47
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol (2009) 1.39
Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol (2011) 1.39
Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine (2008) 1.38
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Forest plots and the interpretation of subgroups. Lancet (2005) 1.37
Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer (2007) 1.33
Clinical and epidemiological issues in mammographic density. Nat Rev Clin Oncol (2011) 1.33
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2012) 1.29
Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer (2007) 1.23
The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer (2012) 1.23
Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int (2007) 1.21
Determinants of percentage and area measures of mammographic density. Am J Epidemiol (2009) 1.20
Screening and adenocarcinoma of the cervix. Int J Cancer (2009) 1.19
Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine (2012) 1.17
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer (2007) 1.15
Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen (2007) 1.08
Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence. Clin Cancer Res (2013) 1.06
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int (2009) 1.06
HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer (2013) 1.05
Recommendations for cervical cancer prevention in Asia Pacific. Vaccine (2008) 1.04
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Res (2008) 1.03
International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int (2007) 1.02
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer (2002) 1.01
[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Epidemiol Prev (2012) 1.01
EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer (2009) 1.00
Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer (2011) 0.99
Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One (2011) 0.99
Routine audit of large-scale cervical cancer screening programs. J Natl Cancer Inst (2008) 0.98
PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes Cancer (2010) 0.98
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol (2003) 0.98
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast (2009) 0.98
Role of aspirin in cancer prevention. Curr Oncol Rep (2013) 0.97
Markers for the identification of late breast cancer recurrence. Breast Cancer Res (2015) 0.97
HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol (2006) 0.97
Further analysis of the ARTISTIC trial. Lancet Oncol (2009) 0.96
Atypical hyperplasia of the breast. N Engl J Med (2015) 0.96
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine (2006) 0.94
APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol (2012) 0.94
Radiotherapy for breast cancer. J Natl Cancer Inst (2005) 0.92
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine (2006) 0.92
Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol (2014) 0.91
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol (2006) 0.91
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy. Cancer (2004) 0.91
Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer (2014) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89